Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2023 | Managing drug resistance in CP-CML with ponatinib and asciminib

Timothy Hughes • 9 Dec 2023

ASH 2023

Chronic Myeloid Leukemia Leukemia Asciminib Ponatinib

ASCEMBL OPTIC

Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, addresses the management of resistant chronic myeloid leukemia in the chronic phase (CP-CML). Findings from the OPTIC (NCT02467270) and ASCEMBL (NCT03106779) studies support the use of ponatinib for patients who are highly drug-resistant and ascminib for patients with high cardiovascular risk profiles. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The ALLG CML13 ASCEND-CML study: high major molecular responses with asciminib treatment for CP-CML

Timothy Hughes • 9 Dec 2023

The efficacy of nilotinib treatment approaches in frontline CML

Timothy Hughes • 12 Jun 2022

Clinical trial updates in CML

Timothy Hughes • 12 Jun 2022

Asciminib: overcoming TKI resistance and reducing toxicity in CML

Timothy Hughes • 12 Sep 2018

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024